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Abstract: Snakes of the genera Pseudocerastes and Eristicophis (Viperidae: Viperinae) are known as the
desert vipers due to their association with the arid environments of the Middle East. These species
have received limited research attention and little is known about their venom or ecology. In this
study, a comprehensive analysis of desert viper venoms was conducted by visualising the venom
proteomes via gel electrophoresis and assessing the crude venoms for their cytotoxic, haemotoxic,
and neurotoxic properties. Plasmas sourced from human, toad, and chicken were used as models
to assess possible prey-linked venom activity. The venoms demonstrated substantial divergence in
composition and bioactivity across all experiments. Pseudocerastes urarachnoides venom activated
human coagulation factors X and prothrombin and demonstrated potent procoagulant activity in
human, toad, and chicken plasmas, in stark contrast to the potent neurotoxic venom of P. fieldi. The
venom of E. macmahonii also induced coagulation, though this did not appear to be via the activation
of factor X or prothrombin. The coagulant properties of P. fieldi and P. persicus venoms varied among
plasmas, demonstrating strong anticoagulant activity in the amphibian and human plasmas but no
significant effect in that of bird. This is conjectured to reflect prey-specific toxin activity, though
further ecological studies are required to confirm any dietary associations. This study reinforces the
notion that phylogenetic relatedness of snakes cannot readily predict venom protein composition or
function. The significant venom variation between these species raises serious concerns regarding
antivenom paraspecificity. Future assessment of antivenom is crucial.
Keywords: Pseudocerastes; Eristicophis; venom; haemotoxic; neurotoxic; cytotoxic; venom variation
Key Contribution: The potent procoagulant venom of Pseudocerastes urarachnoides is described and an
extensive functional and proteomic variation within the desert viper (Pseudocerastes and Eristicophis)
clade is characterised.
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1. Introduction
Snakebite envenoming causes the death or debilitation of hundreds of thousands of
people annually [1]. To address this global health crisis, a better understanding of the
evolution, biology, ecology, venom, and envenoming statistics of medically important
snakes is crucial. Despite this, numerous knowledge gaps surrounding many venomous
species still exist. These gaps are particularly associated with developing regions such
as the Middle East, which has been subject to extended periods of political instability
and ongoing tension. The data-deficient nature of the Middle Eastern herpeto-faunal
literature is exemplified by the relatively recent description of a third species of viperid
snake from the genus Pseudocerastes (Boulenger, 1896), the spider-tailed viper Pseudocerastes
urarachnoides (Viperidae: Viperinae) (Bostanchi, Anderson, Kami, and Papenfuss, 2006)
from western Iran [2,3].
The genus Pseudocerastes, comprised of P. fieldi (Schmidt, 1930), P. persicus (Duméril,
Bibron and Duméril, 1854), and P. urarachnoides is sister to the monotypic species Eristicophis
macmahonii (Alcock and Finn, 1897), which together form a clade colloquially named the
“desert vipers.” The clade is proposed to have split from the most recent common ancestor
of the remaining Eurasian viper genera (Vipera, Daboia, Macrovipera, and Montivipera), to
which they are sister, around 25–33 million years ago (Mya) [4–6]. Further speciation
events within the clade occurred approximately 16–18 Mya (E. macmahonii), 12 Mya (P.
fieldi), and 8 Mya (P. persicus and P. urarachnoides) [4,7]. Distribution data on these species is
incomplete, though they are mostly found throughout the Middle East: E. macmahonii in
the Baluchistan (covering the Iran-Afghanistan-Pakistan border) and the Thar (northwest
India) deserts [8]; P. urarachnoides in western Iran and eastern Iraq [9–11]; P. persicus from
northeast Iraq to western Pakistan (including southern Afghanistan and Iran), as well
as some isolated populations in Oman and the United Arab Emirates (UAE) [12,13]; and
P. fieldi from northern Saudi Arabia, through the south of Israel, Jordan, and Syria, and
across Iraq and southern Iran [3,14]. There appears to be limited range overlap between
these species, though sympatry exists between P. fieldi and P. urarachnoides and between P.
urarachnoides and P. persicus in the northern and southern edges of P. urarachnoides’ range in
western Iran, respectively [13,15]. It is thus posited that all three species of Pseudocerastes
likely exist in sympatry within western Iran [15].
Field studies on the ecology of these snakes are scarce, and information on diet is
largely restricted to that of adult snakes. From what is known, all species inhabit arid
environments. Eristicophis macmahonii can be found in sandy deserts with shifting dunes
and limited vegetation [16], and conceals its body within the loose sand to ambush such
prey items as lizards, rodents, arthropods, and occasionally birds (Figure 1A) [2,8,17,18].
Pseudocerastes fieldi occupies a diversity of arid environments, though their habitat prefer-
ences appear to differ between populations across the range of this species. For example,
Israeli populations tend to be associated with shrubs in semi-deserts with harder substrates
and level ground [19], whereas those found in Jordan are most common in the black basalt
deserts with large rocks amongst loose sandy soils and little to no vegetation [20]. Prey
items include birds, mammals, and lizards, with a possible preference for birds on account
of feathers being abundant in their faeces (Figure 1B) [8,19]. However, of note is the readi-
ness in which captive specimens reportedly consume carcasses, at times even in favour
of live animals. Dead migratory birds may thus form an important proportion of the diet
of some populations of P. fieldi [19]. Pseudocerastes persicus occupies a variety of habitats,
including semi-deserts with varied substrates including sand and rock, as well as arid
plains with vegetation, steep rocky terrain, and rugged slopes typically over 500 m above
sea level (asl) [2,12,21]. For example, in the Hajar Mountains in Oman, this species occurs
in rocky environments between 500 and 2500 m asl, which are subject to relatively cold
and humid conditions [22]; however, in the United Arab Emirates it has also been found
as low as 195 m asl [23]. A generalist feeder, P. persicus predates upon birds, mammals,
lizards, and occasionally arthropods (Figure 1C) [2,8]. Pseudocerastes urarachnoides can
be found on the sheer faces of rocky hills with sparse vegetation [9,24], and adults use
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a highly derived spider-like tail adaptation to lure birds on which they appear to feed
exclusively (Figure 1D) [9,10,24,25]. The caudal lure is not developed in juveniles but forms
progressively as the snakes grow. All desert vipers are assumed to employ caudal luring on
the basis of featuring coloured or modified tail tips; however, this behaviour has only been
documented in P. urarachnoides [9,15]. The tail of P. urarachnoides is the most specialised
and elaborate of the clade—of any reptile, even—perhaps as a reflection of its narrow
ecological niche.
Figure 1. Image and corresponding diet (prey animals depicted in snakes’ order of preference) of (A) Eristicophis macmahonii
(image: Tim Vickers); (B) Pseudocerastes fieldi (image: Gabriel Martinez Del Marmol); (C) Pseudocerastes persicus (image:
Laura and Bobby Bok); (D) Pseudocerastes urarachnoides (image: Laura and Bobby Bok).
Despite their relatively close geographical proximity and apparently similar diets—factors
that are commonly posited to influence the extent of venom variation within a clade—the
venoms of these species differ considerably. For example, E. macmahonii venom possesses
procoagulant properties [26] while P. persicus is anticoagulant [27] and the phospholipase-
dominated venom of P. fieldi is neurotoxic [27]. In a prior proteomic study of the venoms,
the authors posited that P. persicus represents an intermediate condition between the
apotypic venom of P. fieldi and the plesiotypic venom of E. macmahonii [21]. However, a
comparative proteomic or functional analysis of all four desert vipers’ venoms has not
been conducted, and virtually nothing is known about the venom of P. urarachnoides.
To address this knowledge gap, this study analysed the venoms of the desert viper
clade via proteomics and functional venomics. Venom protein profiles were visualised via
one-dimensional gel electrophoresis (1D SDS-PAGE) and venom toxins of P. urarachnoides
were identified by two-dimensional gel electrophoresis (2D SDS-PAGE) followed by liq-
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uid chromatography/mass spectrometry (LC/MS-MS). Venom-induced cytotoxicity was
assessed by incubating the venoms with human melanoma (MM96L), neonatal foreskin
(NFF), and pancreatic tumour (PaTu-T) cell lines for 24 h and visualising cell death via
light microscopy. Neurotoxic venom properties were investigated by chick biventer cervi-
cis assays. The haemotoxic activities of the venoms were evaluated using an automated
coagulation analyser, by thromboelastography, and by measuring venom-induced FX and
prothrombin cleavage. Prey-linked venom activity was investigated via thromboelastog-
raphy using plasma sourced from three model animal groups: toad (amphibian), chicken
(avian), and human (mammalian). A broad, exploratory overview of findings is discussed
in the context of pathophysiology and implications for snakebite envenoming, conjectured
ecological significance, and directions for future research.
2. Results and Discussion
2.1. Venom Proteomics
The 1D SDS-PAGE comparisons revealed substantial differences in the venom protein
composition of the species under study (Figure 2). Each species exhibited a diversity
of venom components ranging from ~12 kDa to >150 kDa in size, and unique bands
were observed in each of the venoms. These differences were particularly evident in the
non-reduced gel profiles (Figure 2B). While banding patterns differ, these gels revealed a
similar (though differential) complexity between P. fieldi and P. persicus venoms, despite
previous SDS-PAGE analyses reporting “very few” protein bands in the former venom
compared with “close to 30” in the latter [27]. It must be noted, however, that <20 kDa
components (predominantly phospholipases (PLA2s) [21]) clearly dominate P fieldi venom,
and additional banding is generally weak throughout both venom profiles. In contrast, the
protein composition of P. urarachnoides and E. macmahonii venoms possessed a number of
intense protein bands that were concentrated in both the upper (>50 kDa) and the lower
(<25 kDa) mass regions of the 1D gels.
A mass spectrometry analysis of 2D gel spots for P. urarachnoides revealed the expres-
sion of numerous snake venom metalloproteases (SVMP), snake venom serine proteases
(SVSP), and L-amino acid oxidases (LAAO) isoforms in the mid (~20–45 kDa) and high
(>50 kDa) molecular weight regions, and an array of PLA2 and lectin isoforms in the
region below 20 kDa (Figure 2C). These toxin classes are abundant in the venoms of most
viperids, including E. macmahonii. However, SVSPs and LAAOs are reduced or absent from
the venoms of both P. persicus and P. fieldi, and SVMPs greatly reduced in the latter [21].
The venom composition of P. urarachnoides therefore appears to share greater similarities
with that of E. macmahonii (most recent common ancestor (MRCA) 16.5 Mya) than that
of its sister species, P. persicus (MRCA 8 Mya) [4]. Notably, however, the PLA2 profile
of P. urarachnoides venom was dominated by neutral phospholipase isoforms, which are
absent or greatly reduced from E. macmahonii and P. persicus venoms, respectively, though
similarly abundant in that of P. fieldi [21].
Of additional interest is the differential banding complexity between reduced and
non-reduced profiles for all species. This suggests that protein complexes and dimers
or trimers are abundant in these venoms. A heterodimeric PLA2 complex, consisting of
one basic and one acidic phospholipase subunit, has been described as the main toxic
component of P. fieldi venom [28,29]. The comparative protein profiles of the reduced and
non-reduced gels in the lower regions (<25 kDa) corroborate the presence of this complex in
P. fieldi and also alludes to the presence of such complexes in each venom (see Neurotoxicity
section for further discussion).
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Figure 2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of (A) 20 µg
Pseudocerastes and Eristicophis venoms run under reducing and denaturing conditions; (B) 20 µg
Pseudocerastes and Eristicophis venoms run under denaturing conditions; and (C) 200 µg Pseudo-
cerastes urarachnoides venom run under reducing, denaturing, and isoelectric focusing (pI) conditions.
Mac = E. macmahonii; ura = P. urarachnoides; fiel = P. fieldi; pers = P. persicus; SVSP = Snake venom
serine protease; LAAO = L-amino acid oxidase; PLA2 = Phospholipase A2; SVMP = Snake venom
metalloprotease.
2.2. Venom-Induced Cytotoxicity
The cytotoxic properties of 10 µg/mL of the venoms in NFF (5000 cells/well), MM96L
(3000 cells/well), and PaTu-T (at 80% confluence) cells were visually assessed by light
microscope imaging at 10× magnification after 24 h of incubation. Though activities of
the venoms differed between cell lines, P. urarachnoides, P. persicus, and E. macmahonii
venoms all variably impacted cell health (Figure 3). However, the venom of P. urarachnoides
appeared to show the most consistent and detrimental effect across all cell lines. It is
thus posited to possess the strongest cytotoxic effects of all the venoms, followed by E.
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macmahonii, though future quantification of the venoms is needed for confirmation. Both
venoms contain large quantities of serine proteases and metalloproteases along with smaller
quantities of L-amino acid oxidases [21], each of which are commonly associated with
cellular and tissue degradation. When all cell lines are viewed in unison, P. persicus venom
demonstrated moderate to strong cytotoxic properties, while P. fieldi venom cytotoxicity was
residual. L-amino acid oxidases are absent from these latter two venoms, and expression
of serine proteases and metalloproteases is greatly reduced compared to the venoms of
P. urarachnoides and E. macmahonii [21]. The variable cytotoxic activities observed in the
microscopy assessment may therefore reflect this differential expression of commonly
cytotoxic toxin groups.
Figure 3. Cytotoxic effects of 10 µg/mL Pseudocerastes and Eristicophis venoms on human pancreatic cancer (PaTu-T),
melanoma (MM96L), and skin (NFF) cells after 24 h of incubation, visualised via light microscopy at 10× magnification.
Rounding and detachment of cells from the well plate (comparative to the control) indicates onset and progression of cell
sickness and death.
2.3. Venom-Induced Neurotoxicity
The venoms were tested for neurotoxicity at the neuromuscular junction by measuring
their ability to abrogate chick biventer cervicis contractions at a concentration of 10 µg/mL.
Of all the venoms, only P. fieldi abolished twitches, with full inhibition occurring after
approximately 50 min (Figure 4A). Following the addition of acetylcholine (ACh), carbachol
(CCh), or potassium chloride (KCl), there was no reduction in agonist responses in the
presence of P. fieldi venom (Figure 4B), which indicates presynaptic neurotoxicity. A
neurotoxic PLA2 complex from P. fieldi venom has been well-characterised and acts at
the presynaptic site to induce irreversible neuromuscular paralysis [30]. While the basic
subunit appears to be that which confers lethality, its potency is greatly enhanced in the
presence of the weakly toxic acidic subunit. The acidic subunit is thus conjectured to
potentiate the lethal activity of the basic phospholipase by acting as a chaperone, inhibiting
non-specific binding and increasing its affinity for its molecular target [28,31]. The diffusion
of such neurotoxic phospholipases throughout a biological system may be hindered by
venom components that disrupt haemostatic balance, such as SVMPs, by inducing local
cell adhesion, inflammation, affecting blood flow rate, and so on. Such interplays may be
an explanation for the inverse trend between SVMPs and PLA2s that can be commonly
observed in viper venoms, including P. fieldi.
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Figure 4. (A) The effects of 10 µg/mL Pseudocerastes and Eristicophis venoms on indirect twitches of 
the chick biventer muscle; (B) Change in contractile response following post hoc addition of agonists 
acetylcholine (ACh; 1 mM), carbachol (CCh; 20 µM), and potassium chloride (KCl; 40 mM). 
Figure 4. (A) The effects of 10 µg/mL Pseudocerastes and Eristicophis venoms on indirect twitches of the chick biventer
muscle; (B) Change in contractile response following post hoc addition of agonists acetylcholine (ACh; 1 mM), carbachol
(CCh; 20 µM), and potassium chloride (KCl; 40 mM).
There was a significant difference in the neurotoxic activity between the venoms
(one-way ANOVA: F4,15 = 174.7, p < 0.0001). Despite this, at the 60 min time point, each
of the other three venoms reduced twitch height by a small but significant degree com-
pared to the negative control (Tukey’s post hoc analysis; mean reduction by E. macmahonii:
13.5%, p = 0.0469; P. urarachnoides: 16.6%, p = 0.0199; P. persicus: 26.5%, p = 0.0002). As this
reduction was minor, it could be explained by either of two scenarios. Other toxin compo-
nents may be inducing tissue damage or fatigue, which over time result in a reduction of
twitch height; alternatively, low levels of neurotoxins may be expressed in these venoms.
While neither can be unequivocally asserted in the absence of comparative transcriptomics,
modest evidence in this study suggests that the latter may be the case. The cytotoxicity
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observations indicate that P. urarachnoides and E. macmahonii possess the greatest cytopathic
activities, while those of P. persicus and P. fieldi were moderate to low, respectively. Should
tissue damage be occurring by cell death, a similar relationship in reduction of neurotox-
icity would be expected. However, in the neurotoxicity assays, the inverse is observed,
whereby the venoms with strongest cytotoxicity induced the smallest reduction in twitch
height. Furthermore, cytotoxic activities are notoriously slow-acting. Cell death in all three
cell lines was observed after 24 h of incubation compared to the 1-h chick biventer assay.
Additionally, should cytotoxic damage have occurred to the tissue, this would likely be
reflected in an increase in base-line tension and a reduction of response following the post
hoc addition of KCl. These factors suggest that the impact of the cytotoxins on the chick
biventer cervicis are limited. Finally, each venom possesses an array of PLA2 isoforms,
some complexes of which are documented as possessing neurotoxic properties [28,31].
Cumulatively, this alludes to the strong possibility that these modest twitch reductions
reflect the activity of a low concentration of neurotoxins. Should this be the case, neurotoxic
PLA2s may have been present in the last common ancestor of this clade.
While the neurotoxic content of P. persicus venom appears low compared to P. fieldi,
very weak venom concentrations are tested in these assays. For example, 10 µg/mL is
probably up to 200 times weaker than the venom concentration that may result in the
body of a 200-g prey animal following envenoming [32]. It is difficult to speculate upon
the susceptibility of different animals to venoms, though it could be reasonably argued
that a weak neurotoxic effect at 10 µg/mL in an in vitro model may offer a significant
contribution to prey subjugation at biologically realistic concentrations. Neurotoxic activity
has been conjectured to offer an advantage in subduing prey with high escape potential,
which could reduce the chance of prey loss following envenoming by limiting distance
travelled [33]. However, this may be contingent upon a bite-and-release strategy, which is
variably employed by P. fieldi and P. persicus depending on prey species and is not employed
by P. urarachnoides or E. macmahonii [8].
2.4. Venom-Induced Coagulant Activity
2.4.1. Coagulation Time, Strength, and Potency
The influence of the venoms on the coagulation of human plasma was tested by
incubating plasma with increasing concentrations of venom until the horizontal asymptote
(minimum clot time) was reached. The minimum clot time (Figure 5A) represents the
strength of the venoms’ clotting activity—i.e., their maximal clot-inducing potential. As
a rule-of-thumb, if a venom takes longer than 80 s to induce clotting at its horizontal
asymptote (i.e., its maximal activity), the resultant clots are likely to be poorly formed
and friable and the venom is not considered to be procoagulant. The mid-curve clot
time (Figure 5B) is the curve point between minimal and maximal activity within these
concentration curves. This value is a proxy for the venom toxins’ affinities for their plasma
targets, represented by the proportional change in clot time per unit of venom over the
curves’ concentration range (between 0.05–30 µg/mL). A smaller relative shift in clot time
with decreasing venom concentrations suggests greater toxin affinities. The EC50 (50%
of the Effective Concentration) (Figure 5C) is the concentration of venom that induces a
clotting response at the mid-point between no effect (i.e., the blank control clotting time of
584 ± 41.3 s) and maximal effect (minimum clot time), representing venom potency. When
viewed in parallel, these parameters provide greater resolution of differences in coagulant
activity between venoms. In particular, the interplay between strength of activity (clotting
times) and potency are an important consideration regarding envenoming.




Figure 5. Coagulant activity of Pseudocerastes and Eristicophis venoms on human plasma in relation 
to (A) Maximal activity (minimum clot time); (B) Strength of activity (mid-curve clot time); and (C) 
Relative venom potency (EC50). Mean ± SD, n = 3. 
All venoms required the presence of calcium for their activity. Minimum clotting 
time was achieved by 20 µg/mL of venom for P. urarachnoides (13 ± 0.1 s) and 30 μg/mL 
for E. macmahonii (47 ± 0.1 s), P. fieldi (101 ± 5.3 s), and P. persicus (89 ± 3.7 s) (Figure 5A). 
These clotting times varied significantly across the clade (one-way ANOVA: F3,7 = 543, p < 
0.0001). While neither P. fieldi nor P. persicus were procoagulant under the aforementioned 
rule-of-thumb, plasma incubated with these venoms clotted at a significantly faster rate 
than the plasma blank control (Tukey’s: p < 0.0001 for each venom). This weak clotting 
activity suggests that they contain procoagulant toxins in their venom, albeit at very low 
levels. The coagulant activity of P. fieldi venom was particularly weak (EC50 = 1288.00 
ng/mL, 99% CI [1144.00, 1450.00] (Figure 5B); mid-curve clotting time = 367 ± 20.0 s (Figure 
5C)), though this remains consistent with case reports documenting instances of mild co-
agulopathy [8]. 
In contrast, the procoagulant activity of P. urarachnoides venom was very strong, with 
clotting times comparable to those achieved by Sri Lankan Russell’s viper venom (Daboia 
russelii) (13.5 s)—a species infamous for its rapid procoagulant activity (see Supplemen-
tary Data). The extremely potent venom of P. urarachnoides (EC50 = 0.07 ng/mL, 99% CI 
[0.04, 0.13]) also retained its procoagulant activity with decreasing venom concentrations. 
At its mid-curve clotting point, 0.4 ± 0.0 µg/mL venom induced a clot in 26 ± 0.5 s—a 
doubling in clot time despite a 50-fold decrease in venom concentration. While there is 
virtually no data available regarding snakebite envenoming by P. urarachnoides, these 
findings indicate that a bite by this species is likely to result in clinically relevant coag-
ulopathy. 
While E. macmahonii venom possessed procoagulant activity, it was significantly 
weaker than that of P. urarachnoides (Tukey’s: p < 0.0001). Furthermore, the venom’s pro-
Figure 5. Coagulant activity of Pseudocerastes and Eristicophis venoms on human plasma in relation to (A) Maximal activity
(minimum cl t time); (B) Strength of activity (mid-curve clot time); and (C) Relative venom potency (EC50). Mean ± SD,
n = 3.
All venoms required the presence of calcium for their activity. Minimum clotting time
was achieved by 20 µg/mL of venom for P. urarachnoides (13 ± 0.1 s) and 30 µg/mL for E.
macmahonii (47 ± 0.1 s), P. fieldi (101 ± 5.3 s), and P. persicus (89 ± 3.7 s) (Figure 5A). These
clotting times varied significantly across the clade (one-way ANOVA: F3,7 = 543, p < 0.0001).
While neither P. fieldi nor P. persicus were procoagulant under the aforementioned rule-of-
thumb, plasma incubated with these venoms clotted at a significantly faster rate than the
plasma blank control (Tukey’s: p < 0.0001 for each venom). This weak clotting activity
suggests that they contain procoagulant toxins in their venom, albeit at very low levels. The
coagulant activity of P. fieldi venom was particularly weak (EC50 = 1288.00 ng/mL, 99% CI
[1144.00, 1450.00] (Figure 5B); mid-curve clotting time = 367 ± 20.0 s (Figure 5C)), though
this remains consistent with case reports documenting instances of mild coagulopathy [8].
In contrast, the procoagulant activity of P. urarachnoides venom was very strong, with
clotting times comparable to those achieved by Sri Lankan Russell’s viper venom (Daboia
russelii) (13.5 s)—a species infamous for its rapid procoagulant activity (see Supplemen-
tary Data). The extremely potent venom of P. urarachnoides (EC50 = 0.07 ng/mL, 99% CI
[0.04, 0.13]) also retained its procoagulant activity with decreasing venom concentrations.
At its mid-curve clotting point, 0.4 ± 0.0 µg/mL venom induced a clot in 26 ± 0.5 s—a
doubling in clot time despite a 50-fold decrease in venom concentration. While there is vir-
tually no data available regarding snakebite envenoming by P. urarachnoides, these findings
indicate that a bite by this species is likely to result in clinically relevant coagulopathy.
While E. macmahonii venom possessed procoagulant activity, it was significantly
weaker than that of P. urarachnoides (Tukey’s: p < 0.0001). Furthermore, the venom’s pro-
coagulant toxins appeared to have a relatively low affinity for their plasma targets as
clotting times declined quickly with decreasing venom concentrations (mid-curve clot
time = 185 ± 5 s by 0.4 ± 0.0 µg/mL venom; a 4-fold reduction in speed). For example, de-
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spite that E. macmahonii venom exhibited a significantly faster maximal clotting speed com-
pared to that of P. persicus (unpaired t-test: t (4) = 20.79, p < 0.00001), there was no significant
difference between their mid-curve clot times (P. persicus mid-curve clot time = 176 ± 5 s
by 0.4 ± 0.1 µg/mL venom; unpaired t-test: t (4) = 1.273, p = 0.2720). Accordingly, the
potency of E. macmahonii venom (EC50 = 58.25 ng/mL, 99% CI [48.66, 68.19]) was lower
than that of P. persicus (EC50 = 36.16 ng/mL, 99% CI [21.39, 52.19]), though this difference
was not significant (unpaired t-test: t (4) = 2.069, p = 0.1074). Overall, the procoagulant
activity of E. macmahonii venom could best be described as moderate. These results also
suggest that the posited low levels of procoagulant toxins within P. persicus venom may
have a high affinity for plasma components. Such coagulant activity could therefore be
an important consideration surrounding P. persicus envenoming as it may contribute to
coagulopathy, even at low venom doses.
2.4.2. Activation of Factor X and Prothrombin
The ability of the venoms to cleave the zymogens FX and prothrombin was tested
by incubating 0.01 µg of venom with 0.01 µg of human FX and human prothrombin and
measuring cleavage activity via fluorometry. Pseudocerastes urarachnoides venom readily
cleaved both prothrombin and FX (Figure 6), therefore likely representing the predominant
factors through which this species induces coagulation. Pseudocerastes persicus and P. fieldi
demonstrated an extremely low degree of zymogen activation, which aligns with the very
weak procoagulant activity of these venoms. Eristicophis macmahonii, however, possessed
FX and prothrombin activation at a similarly low level, discordant with its significantly
stronger clotting times. This suggests that an alternative procoagulant mechanism may
by stimulated by this venom, such as FV activation, and further indicates substantial
divergence in toxin activity between E. macmahonii and P. urarachnoides despite superficial
similarities in their protein profiles and procoagulant activity. It would be informative to
test a broader array of venom-zymogen interactions in the future in order to elucidate the
differences in procoagulant toxin activities of these venoms.
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Figure 6. Activity of 0.01 µg human blood factors X and prothrombin by 0.01 µg of Pseudocerastes and Eristicophis venoms,
measured via fluorometry. Plots show log activity, normalised to positive controls; mean ± SD, n = 5. Activation is calculated
as the relative luminescence units (RLU) emitted by wells containing venom + zymogen + substrate after subtraction of
venom + substrate control RLU. Positive controls = 0.01 µg of human Factor Xa and thrombin.
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2.4.3. Thromboelastography
The clot kinetics of human, toad, and chicken plasmas when incubated with venom
were tested via thromboelastography (TEG). Baseline parameters were established by
measuring the spontaneous clotting of plasmas without venom. To assess influence of the
venoms on clot dynamics, data were normalised to these controls (spontaneous control
= 0%) and potential maxima (100%). Three parameters are presented: “split point,” the
time interval of clot initiation (minutes); “angle,” the rate of clot formation (degrees); and
“maximum amplitude,” the elasticity (and thus strength) of the resultant clot (millimetres).
Statistical analyses compared venom-induced clotting values with the spontaneous controls,
unless otherwise stated.
Factor X is highly conserved between the taxa used as models, and this was reflected
by human FXa activating clotting in each plasma sample (Figure 7).
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human, (ii) toad, and (iii) chicken plasmas when incubated with or without 10 µg/mL Pseudocerastes and Eristicophis ven-
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Figure 8. Reduction (%) of: (A) initiation speed, (B) formation rate, and (C) clot strength of toad plasma by Pseudocerastes
and Eristicophis venoms (10 µg/mL, 30-min incubation) following the addition of clotting activator kaolin. Data (mean ± SD,
n = 3) normalised to clotting values obtained by kaolin-only control (0%).
Human thrombin, however, was unable to clot toad plasma (see Supplementary Data),
which indicates that the cleavage sites of toad thrombin, FV, and/or fibrinogen must differ
sufficiently from those of human. Kaolin, which induces clotting via its negative charge,
was instead used as a control for toad plasma. An additional difference within the toad
plasma was evident in its lack of spontaneous clotting. Therefore, if a venom did not induce
clotting in the toad plasma, it was unclear whether there was an anticoagulant effect or
simply no effect. To circumvent this issue, post hoc testing was conducted on venoms that
did not induce clotting by incubating toad plasma and venom, adding kaolin after 30 min,
and then measuring the ensuing clot for an additional 30 min in order to determine the
extent of clotting inhibition by the venoms (Figure 8).
The venom of E. macmahonii did not induce coagulation in toad plasma. Post hoc
testing indicated that the venom had a weak to moderate anticoagulant effect, slowing
down clot initiation speed by only 13 ± 2.6% and slowing clot formation rate by 65 ± 13.7%.
Clot strength was unaffected (unpaired t-test: t (4), p = 0.5823). The venom did, however,
demonstrate rapid procoagulant activity in both chicken and human plasmas (85 ± 5.7%
and 77 ± 2.5% increase in clot initiation speed, respectively). The venom’s effect on chicken
plasma was slightly greater than on human (Unpaired t-test: t (6) = 2.471, p = 0.0484).
While the venom elevated the rate of clot formation in both plasmas, these increases were
not significant (Chicken: 54 ± 29%; unpaired t-test: t (6) = 1.850, p = 0.1138. Human:
11 ± 21.3%; unpaired t-test: t (6) = 0.5963, p = 0.5728). The venom’s effects on clot strength
were minimal (Chicken: −8 ± 4.7%; unpaired t-test: t (6) = 2.954, p = 0.0255. Human:
−13 ± 11.6%; unpaired t-test: t (4) = 1.473, p = 0.2147).
The lack of strong activity by the E. macmahonii venom in toad plasma suggests that,
overall, the venom is not specialised for acting on toad physiology, at least in the case of
coagulant activity. Despite limited information on the feeding ecology of E. macmahonii and
a small number of amphibian species being sympatric with this viper, niche partitioning
may make it unlikely that toads form an important dietary item, as amphibians are rare in
the shifting, sandy dunes it occupies. Eristicophis macmahonii is said to occasionally consume
rodents [2,8,18,34], and while rodent plasma was not tested here, rodents and humans share
considerable similarity in plasma proteins as well as blood factor sequence identity and
clotting times [35–37]. It is therefore possible that procoagulant venom activity functions to
aid the capture of rodent prey. However, it is interesting to note that this venom also had a
rapid procoagulant effect on chicken plasma, greater even than its effect on human plasma,
despite birds thought to only be occasional prey items [2,8,18,34]. This may be due to a
conserved mechanism of action. Despite conjectures that a diet dominated by endothermic
prey may select for haemotoxic venom [38,39], these results are contrary to this hypothesis
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as the venom of E. macmahonii—a generalist that includes large proportions of ectotherms
such as lizards and arthropods—is predominantly haemotoxic. In contrast, that of P.
fieldi—a generalist that appears to prefer birds and rodents—is dominated by neurotoxins.
Such “ectothermic/endothermic prey” inferences are likely a major over-simplification and
would benefit from greater incorporation of individual species’ ecologies.
Pseudocerastes urarachnoides venom possessed rapid, taxonomically “broad-spectrum”
procoagulant activity, significantly increasing both clot initiation speed and clot formation
rate in each plasma tested (Table 1). There were moderate reductions of clot strength in the
human and chicken plasmas, however, that were not observed in the thrombin- and factor
X-induced clots. This suggests that the venom may be concurrently cleaving fibrinogen in
a degradative manner. It is noteworthy that the venom had strong procoagulant activity
on the toad plasma. This result was unexpected as toad plasma demonstrated generally
low reactivity and P. urarachnoides is said to feed exclusively on birds. However, as the
cleavage site of factor X is highly conserved, even between such divergent lineages as
amphibians and placental mammals [40], this broad coagulant activity may be due to
activation of factor X homologues via their conserved molecular sites. Alternatively, as the
diet of juvenile P. urarachnoides is largely unknown, toads may form an important part of
their diet. Future studies assessing the venom composition of juvenile snakes in parallel
with their ecology are required.
Table 1. Differences between means (±SD) of human, toad, and chicken plasma controls versus those
with P. urarachnoides venom measured via thromboelastography.
P. urarachnoides Venom vs. Spontaneous Control
Difference Between Means ± SD (%); Unpaired t-Test
Plasma (n = 4) Clot Initiation Speed Clot Formation Rate
Human 95 ± 4.3%; t (6) = 22.08, p < 0.000001 61 ± 14.8%; t (6) = 4.08, p = 0.00651
Toad 99 ± 4.3%; t (6) = 23.15, p < 0.000001 63 ± 2.6%; t (6) = 24.37, p < 0.000001
Chicken 96 ± 4.3%; t (6) = 22.46, p < 0.000001 38 ± 10.9%; t (6) = 3.519, p = 0.01254
In human plasma thromboelastograms, P. fieldi and P. persicus venoms prevented a
clot from forming. Thromboelastography provides a more biologically accurate measure
of clotting function than the previously described clotting assays. These results therefore
confirm that the slow clotting times and weak zymogen activation observed in the previous
assays for these species are associated with weak, friable clots. In the chicken plasma, clot
initiation period was lengthened by around 20% by both venoms; however, the ensuing
clots were comparable to (P. persicus) or greater than (P. fieldi) the spontaneous clotting
control in both formation rate and strength. Thus, although clot formation was slightly
delayed, clotting function of chicken plasma was fundamentally uncompromised by these
two venoms. Given that these species are known to consume a high proportion of avian
prey [2,8,19], this suggests that venom-plasma interactions may contribute little to avian
subjugation. However, the reduction in clot initiation period may facilitate the dispersal
of neurotoxic PLA2s that dominate P. fieldi’s venom. Notably, the venoms completely
inhibited clotting of toad plasma (Figure 8), despite that anticoagulant venom activity
was not evident in chicken plasma. Anticoagulant venom activity is common amongst
amphibian specialists [38,41], suggesting that it is a successful means of subjugating toads,
which are otherwise renowned for their resistance to many toxin groups [42]. Where
the toxins inducing this action have been identified in such studies, they are typically
PLA2s [38], and both P. fieldi and P. persicus venom have these toxins in considerable
abundance. Though amphibians are not reported as prey for adult P. fieldi or P. persicus,
ecological studies are lacking. While some studies suggest that P. fieldi and P. persicus adults
prefer feeding on birds, these conclusions are drawn on account of feathers being common
in faeces. However, feathers are not easily digestible in contrast to soft-bodied toads
and this may be biasing such conclusions. It is therefore hypothesised that this observed
anticoagulant activity in toad plasma reflects an ecological adaptation for amphibian
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predation. However, an in-depth analysis of the vipers’ venoms along with their ecology is
required to investigate this hypothesis adequately.
Crucially, these thromboelastograms raise concerns regarding the appropriateness of
building evolutionary models and making inferences on snake ecology and predator-prey
coevolution upon data obtained using only human plasma and crude venoms. This is
particularly true for analyses focussed on species that adopt dietary generalism or prey
upon non-mammalian species. The extreme variation between plasmas observed here
suggest that evolutionary inferences made in such studies may ultimately prove misguided.
Care should be taken to contain such conclusions within the bounds of the chosen model.
3. Conclusions
The most striking observations from this study are i) the substantial divergences in the
bioactivities of these species’ venoms, despite that all members of the clade superficially
share many similarities in their ecology; and ii) the lack of phylogenetic patterns associated
with these activities, despite that there is typically similarity between the venom profiles of
closely related snakes.
Overall, this clade of closely related vipers presents an unusual example of venom
variation. The dietary generalism of P. fieldi is paired with a seemingly specialised proteome
and venom activity (i.e., neurotoxic-dominant), while the dietary generalism of P. persicus
and E. macmahonii is paired with diverse venom biochemistry. In contrast, the diverse
venom proteome of P. urarachnoides is paired with a specialised diet and venom activity
(i.e., coagulating-dominant). These findings superficially deviate from suppositions that
indicate dietary generalism favours toxinological diversity [43] and evade any overarching
evolutionary trends. For example, P. persicus venom shares greater proteomic and functional
similarity to P. fieldi than to P. urarachnoides with whom it is sister. Furthermore, the venom
proteomes of P. urarachnoides and E. macmahonii, which diverged around 16–18 Mya, most
closely resemble that of typical vipers and thus represent the posited plesiotypic condition
of the clade [21]; yet, functionally speaking, both P. urarachnoides and P. fieldi venoms present
an apotypic state—P. fieldi more so if both venom function and proteome are considered.
However, P. urarachnoides arguably presents the most derived predatory characters, should
venom function be considered in parallel with morphological traits.
Given the conjectured shared (though highly variable) expression of neurotoxic PLA2s
and procoagulant toxins within the clade, the common ancestor of this group may have
possessed a venom most resembling that of E. macmahonii. Unfortunately, the lack of
consistent patterns between venom proteome and bioactivity in relation to these species’
phylogenetic relationships or feeding ecologies renders any trends of venom evolution
obscure, begging the question as to what may be influencing their divergence. Venom vari-
ation is commonly linked with populational or age-driven differences in prey availability
or endothermic/ectothermic prey groupings [38,39,44]. However, these paradigms appear
incongruent with this level of venom variation relative to the overlap in range, age, diet,
and/or habitat between these snakes. Other studies investigating venom variation have
found no strong link with diet but correlated venom composition with climate [33,45]. The
influence of climate may be particularly salient in arid regions, such as the Middle East.
The blood chemistry of reptiles is known to fluctuate wildly, depending on metabolic state,
temperature, and fasting period [46]. These fluctuations are amplified in desert species,
whereby dehydration affects blood volume, osmotic concentration, and pH. The stability
of a prey species’ biochemical environment may, in turn, affect venom function and play a
key role in driving venom evolution, leading to divergences such as those observed in this
study. Such interpretations are unfortunately confounded by a lack of natural history infor-
mation pertaining to these species. Future studies addressing this evolutionary enigma
would benefit from the inclusion of robust dietary data and the integration of broader
ecological variables such as morphology along with predation strategies, abiotic factors,
and biogeographical history.
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Regardless of evolutionary drivers, this study reinforces the notion that phylogenetic
relatedness of snakes cannot readily predict venom protein composition or activity, even
where overlaps in ecology are evident. This considerable venom variation raises serious
concerns regarding the paraspecificity of the Razi polyvalent antivenom, which is specific
for P. persicus—the venom of which possesses the weakest activity of these species (accord-
ing to human-oriented in vitro models). Future assessment of antivenom cross-reactivity is
therefore crucial.
4. Materials and Methods
4.1. Venom Samples
All venom work was undertaken under the University of Queensland IBSC approval
#IBC134BSBS2015. Eristicophis macmahonii venom was collected from 3 adult male snakes
from the Nushki district (30.12◦ N 67.01◦ E) of Balochistan, Pakistan by SAA. Pseudocerastes
fieldi and P. persicus venoms were purchased from Latoxan. Pseudocerastes urarachnoides were
collected under the approval of NIMAD # 942485 by PG and BF. Venoms were immediately
flash frozen in liquid nitrogen and were subsequently lyophilised and stored at −80 ◦C until
use. Samples were pooled to account for any potential variation in toxin expression between
individuals. The lyophilised venoms were reconstituted to a working stock concentration
of 1 mg/mL in 50% deionised H2O (Milli-Q) and 50% glycerol (Sigma-Aldrich) to prevent
freezing and thus reduce enzyme degradation associated with freeze-thaw cycles. Working
stock aliquots were stored at −20 ◦C and used for all subsequent analyses.
4.2. Plasma
Human plasma was sourced from the Australian Red Cross (44 Musk Street, Kelvin
Grove, Queensland, Australia, 4059) under human ethics approval number 2016000256.
Two batches of pooled human plasma (Lot#3379236: 120 mL of Rhesus O+; Lot#3376558:
874 mL of Rhesus AB+) were further combined and aliquoted. The aliquots were flash
frozen in liquid nitrogen and stored at −80 ◦C. Immediately prior to use for experimen-
tation, aliquots were defrosted by immersing in a water bath for 5 min at 37 ◦C. Clotting
time parameters were established for the plasma by measuring clot formation (in triplicate)
in the presence and absence of an activator: 46–48 s (s) and 300–500 s, respectively (see “co-
agulation analyses” for protocol). To check for plasma degradation and ensure the clotting
parameters of the plasma aliquots were consistent over time, positive and negative controls
were conducted prior to each experimental assay; namely, clotting time was measured
in the presence and absence of an activator and compared to pre-established parameters.
Chicken and toad bloods were extracted from anaesthetised animals by a trained veteri-
narian under the University of Queensland Animal Ethics approval SBS/019/14/ARC.
Blood was citrated (3.2%) and spun at 15,000 relative centrifugal force (RCF) for 15 min,
supernatant (plasma) extracted and aliquoted. The aliquots were flash frozen in liquid
nitrogen and stored at −80 ◦C until use. Immediately prior to use for experimentation,
aliquots were defrosted by immersing in a water bath for 5 min at 37 ◦C.
4.3. Proteomics
4.3.1. Venom SDS-PAGE Gel Electrophoresis
One mm 12% SDS-PAGE gels were prepared using the following recipe for resolving
gel layer: 3.3 mL deionised H2O, 2.5 mL 1.5 M Tris-HCl buffer pH 8.8 (Tris—Sigma-Aldrich,
St. Louis, MO, USA; HCl—Univar, Wilnecote, UK), 100 µL 10% SDS (Sigma-Aldrich, St.
Louis, MO, USA), 4 mL 30% acrylamide mix (Bio-Rad, Hercules, CA, USA), 100 µL 10%
APS (Bio-Rad, Hercules, CA, USA), 4 µL TEMED (Bio-Rad, Hercules, CA, USA); and
stacking gel layer: 1.4 mL deionised H2O, 250 µL 0.5 M Tris-HCl buffer pH 6.8, 20 µL
10% SDS (Sigma-Aldrich, St. Louis, MO, USA), 330 mL 30% acrylamide mix (Bio-Rad,
Hercules, CA, USA), 20 µL 10% APS (Bio-Rad, Hercules, CA, USA), 2 µL TEMED (Bio-Rad,
Hercules, CA, USA). 10× gel running buffer was prepared using the following recipe:
250 mM Tris (Sigma-Aldrich, St. Louis, MO, USA), 1.92 M glycine (MP Biomedicals, Santa
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Ana, CA, USA), 1% SDS (Sigma-Aldrich, St. Louis, MO, USA), pH 8.3. For the 1D gels,
venom samples were prepared with and without 5% 2-mercaptoethanol (reduction and
no reduction of disulphide bridges, respectively), and were boiled at 100 ◦C for 5 min to
denature proteins. Twenty µg venom samples were loaded into the gels and were run in
1× gel running buffer at room temperature for 20 min at 90 V (Mini Protean3 power-pack
from Bio-Rad, Hercules, CA, USA) and then 120 V until the dye front approached the
bottom of the gel. Gels were then stained with colloidal coomassie brilliant blue G250 (34%
methanol (VWR Chemicals, Tingalpa, QLD, Australia), 3% orthophosphoric acid (Merck,
Darmstadt, Germany), 170 g/L ammonium sulphate (Bio-Rad, Hercules, CA, USA), 1 g/L
coomassie blue G250 (Bio-Rad, Hercules, CA, USA), and de-stained in deionised H2O
(Milli-Q).
For 2D gels, 300 µg venom samples were loaded onto immobilised pH gradient (IPG)
strips (Bio-Rad ReadyStrip, non-linear pH 3–10, 7 cm) and incubated overnight at room
temperature. Isoelectric focussing was conducted using a PROTEAN i12 IEF CELL (Bio-
Rad Lab) under the following conditions: 50 µA current; 100 V for 1 h, 500 V for 1 h,
1000 V for 1 h, and 8000 V until 98,400 V/h. To reduce and alkylate the samples, IPG strips
were incubated in a reducing equilibration buffer (50 mM Tris–HCl, pH 8.8, 6 M urea, 2%
SDS, 30% glycerol, 2% DTT) for 10 min, followed by further incubated for 20 min in an
alkylating equilibration buffer (50 mM Tris–HCl, pH 8.8, 6 M urea, 2% SDS, 30% glycerol,
2.5% iodoacetamide). The strips were then rinsed with SDS-PAGE running buffer and
positioned on top of 12% polyacrylamide gels using 0.5% agarose. Gels were run at 4 ◦C
with a current of 10 mA/per gel for 20 min followed by 20 mA/per gel for the rest of the
run until the bromophenol dye front was within 0.5 cm of the base of the gel. After the run,
gels were briefly washed with water and stained with 0.2% colloidal Coomassie brilliant
blue G250 overnight.
Visible spots were picked from the gel, washed with 100 µL 50 mM ABC twice and
destained with 50 mM ABC/50% acetonitrile (ACN), and then incubated with 100% ACN
until opaque. Twenty µL of trypsin solution (20 µg trypsin in 100 µL 1 mM HCl and
900 µL of 40 mM ammonium bicarbonate (ABC)) was diluted in 380 µL 40 mM ABC,
then 30 µL was added to gel spots and incubated overnight at 37 ◦C. Subsequently, spots
were removed from solution and peptides eluted by adding 1% trifluoroacetic acid (TFA),
incubating for 20 min, transferring solution and then repeating with 5% ACN/1% TFA.
Solutions were centrifuged at 16,000 RCF for 10 min and supernatant extracted. Solutions
were then ziptipped by wetting tip (Millipore ZTC18S096, Sigma-Aldrich, St. Louis, MO,
USA) with 100% ACN, equilibrating with 5% ACN/0.1% TFA, loading sample, washing tip
with 5% ACN/0.1% TFA, eluting sample with 60% ACN/0.1% TFA, dehydrating sample
and then and resuspending in 0.1% formic acid.
4.3.2. Liquid Chromatography-Mass Spectrometry
Peptides extracted from in-gel tryptic digestion were analysed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) using an Agilent Zorbax stable bond C18 column
(2.1 mm × 100 mm, 1.8 µm particle size, 300 Å pore size) on a Shimadzu Nexera UHPLC
system (Shimadzu, Kyoto, Japan) coupled to an AB SCIEX 5600 Triple TOF mass spectrom-
eter (AB Sciex, Concord, ON, Canada). The chromatographic elution was achieved at a
flow rate of 400 µL/min via a gradient of 1 to 40% solvent (90% acetonitrile, 0.1% formic
acid) over 4 min. The MS/MS spectra were acquired at a rate of 20 scans per second with
a cycle time of 2.3 s, and the resultant 20 most intense ions were obtained and searched
against UniProt databanks using Protein Pilot v4.0 software (AB SCIEX, Foster City, CA).
4.4. Cytotoxicity
Pancreatic tumour (PaTu-T) cells, melanoma patient derived cells (MM96L), and
human neonatal foreskin fibroblasts (NFF) were selected as representatives of both healthy
and unhealthy cells from different organs to account for any variation in cell types. Cells
were maintained in RPMI medium supplemented with 1% penicillin-streptomycin and
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10% foetal bovine serum (FBS). Cells were trypsinised (0.25% trypsin) and seeded 24 h
prior to the experiments in 96-well flat bottom plate at a density of 5000 and 3000 cells/well
for NFF and MM96L cells, respectively, and at 80% confluence for PaTu-T cells. Plates
were incubated at 37 ◦C in a 5% CO2-95% humidified environment. A minimum of three
replicates were conducted per treatment. Cell death was visualised via light microscopy
using Zeiss Axiovert 200 with a Plan- Apochromat 63 × 1.4 numerical aperture after 24h of
treatment with Pseudocerastes or Eristicophis venoms at 10 µg/mL.
4.5. Neurotoxicity
Male chicks (Gallus gallus) were euthanized with CO2 between 4–10 days after hatching
(animal ethics approval number 22575, MARP2 committee, Monash University). Replicates
were run using tissues of different ages to account for differences in effects related to tissue
development. Chick biventer cervicis nerve-muscle were dissected and preparations were
mounted under 1 g tension in 5 mL organ baths containing physiological salt solution (in
mM; 118.4 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2, 25 NaHCO3, and 11.1 glucose)
at 34 ◦C and bubbled with carbogen (95% O2; 5% CO2). Electrodes were placed around the
tendon of the biventer muscle. Electrical stimulation of the motor nerve (0.2 ms duration,
0.1 Hz, supramaximal V) using a Grass S88 stimulator (Grass Instruments, Quincy, MA,
USA) evoked indirect twitches. Selective stimulation of the nerve was confirmed by
the abolition of twitches with d-tubocurarine (10 µM), a nicotinic acetylcholine receptor
(nAChR) competitive antagonist. Tissues were then washed repeatedly with physiological
salt solution to restore twitch responses to nerve stimulation. The stimulation was ceased,
and the contractile responses to acetylcholine (1 mM ACh for 30 s), carbachol (20 µM CCh
for 60 s), and potassium chloride (KCl; 40 mM for 30 s) were obtained and recorded. The
organ bath was then washed, and electrical stimulation was resumed and maintained for
30 min to allow the preparation to equilibrate. Venom (10 µg/mL) was added to the organ
bath and the twitch height was recorded until twitch response was abolished. If twitch
response did not cease, measurements were stopped at 60 min. The stimulator was turned
off again and the bath was washed. Contractile responses to ACh, CCh, and KCl were
obtained again to compare with responses prior to venom addition. The twitch responses
to electrical stimulation and contractile responses to agonists (ACh, CCh, and KCI) were
measured using a Grass FT03 force displacement transducer (Grass Instruments, Quincy,
MA, USA) and recorded on a PowerLab system (ADInstruments Pty Ltd., Bella Vista, NSW,
Australia). At least four replicates were run for each venom.
4.6. Coagulation Analyses
4.6.1. Clot Formation Time
Coagulant activity was assessed by incubating the venoms with human plasma and
measuring time until clot formation. The coagulation analyses were performed using a
Stago STA-R Max® automated coagulation analyser and Stago Analyser software v0.00.04
(Stago, Asnières sur Seine, France). Venom working stock was manually diluted to
0.1 mg/mL in Owren Koller (OK) Buffer (Stago Cat# 00360) and loaded into the anal-
yser. All subsequent dilutions, steps, and measurements were automated. Venom-induced
clotting times were measured over a 9-point dilution series (µg/mL: 30.00, 20.00, 10.00, 4.00,
1.67, 0.67, 0.25, 0.13, and 0.05). Assay conditions were as follows: 50 µL venom (further
diluted in OK Buffer, as appropriate, to achieve desired concentration) was incubated with
50 µL of CaCl2 (0.025 M, Stago Cat# 00367), 50 µL phospholipid (cephalin prepared from
rabbit cerebral tissue from STA C.K. Prest standard kit, Stago Cat# 00597, solubilised in
5 mL OK Buffer), and 25 µL of OK Buffer for 120 s at 37 ◦C. 75 µL of human plasma was
then added and time until clot formation measured by the analyser using a viscosity-based
detection system. Each dilution series was repeated in triplicate. To measure toxin co-factor
dependency, the above assay was repeated in the presence and absence of calcium and/or
phospholipid. Conditions were identical except for 50 µL OK buffer being used in place
of the absent co-factor in order to maintain a consistent final volume (250 µL). Plasma
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negative controls were conducted under identical conditions except for 50 µL of blank
solution (v/v: 5% glycerol, 5% H2O, 90% OK buffer) substituting the venom. Positive
controls were conducted by incubating 50 µL Kaolin (STA C.K. Prest standard kit, Stago
Cat#00597) with 50 µL plasma for 120 s at 37 ◦C. 50 µL CaCl2 (0.025 M, Stago Cat#00367)
was then added and time until clot formation measured.
4.6.2. Factor X and Prothrombin Activation
To measure the activation of the coagulation factor Factor X (FX) by the venom,
10 µL venom (containing 0.05 µg, 0.1 µg, and 0.5 µg dry venom weights) was plated in
at least triplicate on a 384 well plate along with 10 µL FX (Haematologic Technologies,
Inc., 57 River Road, Unit 1021, Essex Junction, VT 05452 USA) (0.1 µg dry weight) and
10 µL phospholipid (cephalin prepared from rabbit cerebral tissue from STA C.K. Prest
standard kit, Stago Cat#00597, solubilised in Owren Koller (O.K.) Buffer). To account for
direct substrate cleavage by the venom, 10 µL venom (containing 0.05 µg, 0.1 µg, and
0.5 µg dry venom weights) was plated in triplicate on a 384-well plate along with 10 µL
phospholipid and 10 µL buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4) to substitute the
FX for later subtraction. Ten µL (0.1 µg dry weight) of FXa (Haematologic Technologies,
Inc via United Bioresearch, Sydney.) in at least triplicate was used as a positive control.
Negative control consisted of 20 µL dilution buffer and 10 µL phospholipid. Activity was
measured by adding 70 µL quenched Fluorogenic Peptide Substrate Cat#ES002 (R and D
systems, Minneapolis, Minnesota, USA) (10 µL substrate in 5mL enzyme buffer: 150 mM
NaCl, 50 mM Tris-HCl, 5 mM CaCl, pH 7.4). Fluorescence was monitored (excitation at
390 nm and emission at 460 nm) at 37 ◦C over 400 min or until activity ceased. To measure
prothrombin activation, test conditions were identical except prothrombin (Haematologic
Technologies, Inc.) was used in place of FX, thrombin (Haematologic Technologies, Inc.) in
place of FXa, and Fluorogenic Peptide Substrate Cat#ES011 (measured at 390 nm/460 nm)
in place of substrate Cat#ES002. Data were normalised against no reaction (0%) and the
positive control (100%) using GraphPad Prism version 8.0.0 for iOS (GraphPad Software,
San Diego, California, USA, www.graphpad.com).
4.6.3. Thromboelastography
The effects of venoms on clot dynamics of plasma were measured using a Thromboelastograph®
5000 Haemostasis analyser (Haemonetics®, Haemonetics Australia Pty Ltd., Sydney, Aus-
tralia). This machinery consists of a stationary pin suspended by a torsion wire into the cup.
The cup oscillates, and as the clot develops the changes in the viscoelasticity of the fluid
are detected by the pin and wire, which act as a torque transducer and generates a “trace”
output. For the experiments, 189 µL of human, chicken, or toad plasma was combined with
72 µL CaCl2 (25mM stock solution Stago Cat# 00367 STA), 72 µL phospholipid (STA C·K
Prest standard kit, Stago Cat# 00597; solubilised in Owren Koller (OK) buffer), and 20 µL
OK buffer in an assay cup (Haemonetics Australia Pty Ltd., North Rye, Sydney, Australia).
In the final step, 7 µL venom (1 mg/mL in 1:1 glycerol:deionised H2O) was added, pipette
mixed, and then the machine was immediately started. Tests were run at 37 ◦C and mea-
sured for 30 min. Negative and positive controls followed identical methods, except 7 µL
of 1:1 glycerol:deionised H2O (negative control) and 7 µL thrombin, FXa (STA®-Liquid
Anti-Xa, Stago), and/or kaolin (STA C.K. Prest standard kit, Stago Cat# 00597) (positive
controls) replaced the 7 µL venom in the final step. As these plasmas had low levels of
platelets, values attained in these assays are not comparative to in vivo coagulation. For
example, clot strength is compromised by the lack of fibrin-binding platelets, which makes
assessment of the venoms’ influence on such parameters difficult. However, blood factors
that are upstream in the coagulation cascade, such as FXII, are known to spontaneously
convert into their active form. This initiates the coagulation cascade despite the absence
of an activator, and the resulting “spontaneous” clot is structured according to the native
proportions of blood factors in the platelet-poor plasma used in in vitro assays. The venom
data were therefore normalised against the spontaneous clotting control data (spontaneous
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clot: 0%; potential maxima: 100%) to assess the venoms’ influence on in vitro coagulation
cascade kinetics.
4.7. Statistics
Data were graphed and analysed using GraphPad Prism version 8.0.0 for iOS (Graph-
Pad Software, San Diego, CA, USA, www.graphpad.com). Venom neurotoxicity data were
normalised against the controls and tested for normality using Shapiro-Wilk, Kolmogorov
Smirnov, and Q-Q plots. Contractile heights at 60 min were compared via one-way ANOVA
with Tukey’s post hoc and paired t-tests (control vs. venom) using Prism default settings
with 95% confidence interval. To analyse the data obtained in the Stago coagulation
analyses, dose-response plasma coagulation curves were normalised against maximal re-
sponse of the venom’s clotting time (100%) and blank plasma control spontaneous clotting
time (0%). EC50s were then calculated using the non-linear regression (log)dose vs. (nor-
malised)response model—variable slope with Shapiro–Wilk, Kolmogorov Smirnov, and
Q-Q plot diagnostic tests for normality and confidence intervals set to 95%. Clotting times
were compared using one-way ANOVA (grouped analyses) with Tukey’s post hoc analysis
or unpaired T-tests using Prism default settings with a 99% confidence interval. Throm-
boelastography data were tested for normality using Shapiro-Wilk, Kolmogorov Smirnov,
and Q-Q plot diagnostic tests. The data were normalised against the spontaneous clotting
control data for each plasma (spontaneous clot time: 0%; potential maxima: 100%). As pos-
itive controls (thrombin and FXa) were of human origin, they could not be used to obtain
maximal values of clotting parameters against which to normalise venom-induced clot data.
“Potential maxima” values for clot maximum amplitude and angle for chicken and toad
plasma were therefore obtained and estimated from previous studies that characterised
the clotting parameters of alike animal plasmas under comparable methodologies [47–49].
Venom-induced values were compared to spontaneous controls using unpaired t-tests with
99% confidence intervals.
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